DE69634662D1 - Schmerzlindernde verwendung von n-l-alpha-aspartyl-l-phenylalanine-1-methylester - Google Patents

Schmerzlindernde verwendung von n-l-alpha-aspartyl-l-phenylalanine-1-methylester

Info

Publication number
DE69634662D1
DE69634662D1 DE69634662T DE69634662T DE69634662D1 DE 69634662 D1 DE69634662 D1 DE 69634662D1 DE 69634662 T DE69634662 T DE 69634662T DE 69634662 T DE69634662 T DE 69634662T DE 69634662 D1 DE69634662 D1 DE 69634662D1
Authority
DE
Germany
Prior art keywords
aspartyl
alpha
methyl ester
personal
phenyl alanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69634662T
Other languages
English (en)
Other versions
DE69634662T2 (de
Inventor
B Edmundson
V Manion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Application granted granted Critical
Publication of DE69634662D1 publication Critical patent/DE69634662D1/de
Publication of DE69634662T2 publication Critical patent/DE69634662T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A23L27/31—Artificial sweetening agents containing amino acids, nucleotides, peptides or derivatives
    • A23L27/32—Artificial sweetening agents containing amino acids, nucleotides, peptides or derivatives containing dipeptides or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Seasonings (AREA)
DE69634662T 1995-06-23 1996-06-21 Schmerzlindernde verwendung von n-l-alpha-aspartyl-l-phenylalanine-1-methylester Expired - Fee Related DE69634662T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US590409 1990-09-28
US47995P 1995-06-23 1995-06-23
US479 1995-06-23
US08/590,409 US5654334A (en) 1995-06-23 1996-01-25 Analgesic use of N-L-α-aspartyl-L-phenylalanine 1-methyl ester
PCT/US1996/010716 WO1997000692A1 (en) 1995-06-23 1996-06-21 ANALGESIC USE OF N-L-α-ASPARTYL-L-PHENYLALANINE 1-METHYL ESTER

Publications (2)

Publication Number Publication Date
DE69634662D1 true DE69634662D1 (de) 2005-06-02
DE69634662T2 DE69634662T2 (de) 2006-03-02

Family

ID=26667704

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69634662T Expired - Fee Related DE69634662T2 (de) 1995-06-23 1996-06-21 Schmerzlindernde verwendung von n-l-alpha-aspartyl-l-phenylalanine-1-methylester

Country Status (8)

Country Link
US (2) US5654334A (de)
EP (1) EP0833651B1 (de)
JP (1) JP2000502318A (de)
AT (1) ATE293986T1 (de)
AU (1) AU722460B2 (de)
CA (1) CA2225462A1 (de)
DE (1) DE69634662T2 (de)
WO (1) WO1997000692A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654334A (en) * 1995-06-23 1997-08-05 Oklahoma Medical Research Foundation Analgesic use of N-L-α-aspartyl-L-phenylalanine 1-methyl ester
CA2266098A1 (en) * 1996-09-26 1998-04-02 Oklahoma Medical Research Foundation Use of n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester and its derivatives in disease regression
US6156795A (en) * 1997-12-22 2000-12-05 Oklahoma Medical Research Foundation N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester and its derivatives for appetite enhancement
US6326400B1 (en) 1999-08-27 2001-12-04 Allen B. Edmundson N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester and its derivatives for appetite enhancement
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
ATE321564T1 (de) * 1999-09-25 2006-04-15 Oklahoma Med Res Found Aspartamderivate zur senkung der blutviskosität
US6919374B1 (en) 1999-09-25 2005-07-19 Oklahoma Medical Research Foundation Viscosity modulating substance and use thereof
JP2005060311A (ja) * 2003-08-13 2005-03-10 Mochida Pharmaceut Co Ltd Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
US7288527B2 (en) * 2004-04-27 2007-10-30 Oklahoma Medical Research Foundation Inhibition of allergic contact dermatitis by N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester
US20050277597A1 (en) * 2004-06-10 2005-12-15 Oklahoma Medical Research Foundation Use of N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester to treat sunburn and other burns
WO2007112000A2 (en) * 2006-03-24 2007-10-04 Wyeth Treatment of pain
KR20240051283A (ko) 2013-12-24 2024-04-19 버지니아 커먼웰스 유니버시티 산소첨가된 콜레스테롤 술페이트 (ocs) 의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492131A (en) * 1966-04-18 1970-01-27 Searle & Co Peptide sweetening agents
US5053396A (en) * 1985-08-27 1991-10-01 Blass David H Therapeutic composition
IT1209667B (it) * 1985-11-12 1989-08-30 Zambon Spa Composizione effeverscente adattivita' analgesica.
EP0358758A1 (de) * 1987-04-09 1990-03-21 Terumo Kabushiki Kaisha Mittel zur abtrennung von b-lymphozyten und mittel zur klärung von körperflüssigkeiten
JPH0832627B2 (ja) * 1988-02-16 1996-03-29 三井東圧化学株式会社 二日酔予防治療剤
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
FR2649611A1 (fr) * 1989-07-13 1991-01-18 Philippe Perovitch Procede de preparation galenique d'une composition therapeutique notamment a base d'aspirine
IT1264856B1 (it) * 1993-06-21 1996-10-17 Zambon Spa Composizione farmaceutica ad attivita' analgesica
BE1007099A5 (fr) * 1993-11-22 1995-03-14 Messadek Jallal Activite medicamenteuse de l'aspartame.
FR2714064B1 (fr) * 1993-12-16 1996-03-08 Edmond Creppy Aspartame pour son application en tant que substance thérapeutiquement active.
US5654334A (en) * 1995-06-23 1997-08-05 Oklahoma Medical Research Foundation Analgesic use of N-L-α-aspartyl-L-phenylalanine 1-methyl ester

Also Published As

Publication number Publication date
US5998473A (en) 1999-12-07
EP0833651B1 (de) 2005-04-27
US5654334A (en) 1997-08-05
AU722460B2 (en) 2000-08-03
CA2225462A1 (en) 1997-01-09
DE69634662T2 (de) 2006-03-02
AU6287896A (en) 1997-01-22
EP0833651A1 (de) 1998-04-08
WO1997000692A1 (en) 1997-01-09
JP2000502318A (ja) 2000-02-29
ATE293986T1 (de) 2005-05-15

Similar Documents

Publication Publication Date Title
MY119403A (en) Novel compounds with analgesic effect.
US5091171B2 (en) Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
DE69634662D1 (de) Schmerzlindernde verwendung von n-l-alpha-aspartyl-l-phenylalanine-1-methylester
KR930009607A (ko) 증식성 질환의 치료를 위한 다이피리다몰
MX9600065A (es) Polisacaridos acidicos reticulados y sus usos.
CA2214097A1 (en) Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
GB2340039B (en) Improved delivery of drugs to mucosal surfaces
NO941317L (no) System for forbedret topisk levering av medikamenter med öket hudpenetrering
CA2150937A1 (en) Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
GR3032207T3 (en) 2-Bromomelatonin in the therapy of sleep disorders
BR9711671A (pt) Tratamento com ácido graxo.
AU6414994A (en) Composition and method for reducing toxicity of biologically-active factors
DK1572167T3 (da) Transdermal buprenophindoseringsbehandlingsplan for analgesi
ATE320814T1 (de) Verwendung von zinkhyaluronat gegen magengeschwür
GR3015431T3 (en) Use of acetyl L-carnitine in the therapeutic treatment of coma.
IL126175A0 (en) Method or treating heart failure with endothelin antagonists and pharmaceutical compositions containing the same
PT1058544E (pt) Inibicao da actividade do tnf
EP0906757A3 (de) Analgetische Zusammensetzung welche Moxonidine und ein Opioid-Analgetika enthält
UA26886C2 (uk) Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість
MX9804798A (es) Nuevos compuestos con efecto analgesico.
MX9804797A (es) Nuevos compuestos con efecto analgesico.
Drusan et al. The granulocytopenic cancer patient. When and how to initiate empiric antimicrobial therapy.
RU92015086A (ru) Препарат для аналгезии на основе морфина
MD1296F1 (en) The Nicolau method of treatment of the lichen planus
DE59809592D1 (de) Verwendung von putamen ovi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee